Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AKAN vs CISS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AKAN Captures Overall Composite Edge (39.8 SELL vs 33.6 SELL), While CISS Leads 4–2 on Growth & Valuation Pillars

AKAN Overall Winner 6-Pillar Tally: AKAN 2 – 4 CISS Matrix Metrics: AKAN 3 – 5 CISS

As of Nov 20, 2026, Akanda Corp. Common Shares (AKAN) captures the overall head-to-head institutional edge over C3is Inc. (CISS) on higher Unified Composite conviction (39.8/100 SELL vs. 33.6/100 SELL) after splitting the core matrix 3–5 (led by Valuation Multiples, Options & Positioning), while CISS wins 4–2 across the 6-pillar growth and valuation breakdown. AKAN trades at $4.23 (N/M Forward P/E, -1254.5% operating margin) versus CISS at $1.23 (N/M Forward P/E, 24.6% operating margin).

  • Growth vs. Quality Trade-Off: AKAN earns the overall head-to-head edge with a stronger Unified Composite Score (39.8/100 SELL vs. CISS 33.6/100 SELL) and 4.82β · 524% Vol risk profile, whereas CISS leads top-line expansion (+249.0% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although AKAN compares more favorably head-to-head, both AKAN (39.8/100 SELL) and CISS (33.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: AKAN is currently in a Breakdown options structure phase (RSI 75.2); meanwhile CISS is in a Breakdown options structure phase (RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKAN vs CISS
AKAN NASDAQ Head-to-Head Winner
Akanda Corp. Common Shares
Medicinal Chemicals & Botanical Products
$4.23
+23.32% 1D
Market Cap $12.2M
TTM Revenue $662,469
Forward P/E N/M
Beta / 30D Vol 4.82β · 524% Vol
Unified Composite Score
39.8 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 75
RSI-14: 75.2 · SMA20: $1.52 · SMA50: $1.88
CISS NASDAQ
C3is Inc. Common Stock
Deep Sea Foreign Transportation Of Freight
$1.23
+4.24% 1D
Market Cap $991,199
TTM Revenue $36.2B
Forward P/E N/M
Beta / 30D Vol 11.91β · 1054% Vol
Unified Composite Score
33.6 / 100 SELL
Tech 5.0 Fund 29.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $1.05 · SMA50: $0.95

6-Pillar Scorecard Institutional Category Breakdown (AKAN 2 – 4 CISS)

Columns: Metric · AKAN · CISS
1. Valuation Multiples AKAN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 18.5x N/M
2. Growth & Scale CISS
Revenue Growth (YoY) +21.9% +249.0%
Earnings Growth (YoY) +0.0% +193.3%
TTM Revenue (USD) $662,469 $36.2B
Market Cap $12.2M $991,199
3. Profitability & Quality CISS
Gross Margin -12.0% 68.1%
Operating Margin -1254.5% 24.6%
Net Profit Margin 0.0% 27.4%
Return on Equity (ROE) -60.9% 17.1%
4. Balance Sheet & Cash Flow CISS
Cash Generation (TTM) -$7.9M EBITDA $13.4B EBITDA
Cash Flow Margin N/A 36.9% EBITDA Mgn
Net Cash / Leverage -60.9% ROE $384.31 Book/Sh · 17.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AKAN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CISS
OpEx & R&D Intensity N/A 43.5% of Rev ($15.8B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Marine Shipping Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKAN (3) vs CISS (5)
Institutional Metric AKAN CISS Criterion Row Edge
Market Capitalization
Scale
$12.2M $991,199 Larger Scale AKAN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+21.9% +249.0% Higher Growth CISS
Operating Margin (TTM)
Profitability
-1254.5% 24.6% Higher Margin CISS
Net Profit Margin
Profitability
0.0% 27.4% Higher Margin CISS
Return on Equity (ROE)
Capital Efficiency
-60.9% 17.1% Higher ROE CISS
52-Week Range Position
Momentum
5% ($0–$79) 20% ($0–$6) Stronger Trend CISS
Beta / 30D Volatility
Risk Regime
4.82β · 524% Vol 11.91β · 1054% Vol Lower Realized Risk AKAN
Unified Institutional Score
Composite Signal
39.8 / 100 (SELL) 33.6 / 100 (SELL) Higher Composite AKAN
Trailing 12M Revenue (USD)
Operating Scale
$662,469 $36.2B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-12.0% 68.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.9M EBITDA (-60.9% ROE) $13.4B EBITDA ($384.31 Book/Sh · 17.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AKAN +132.6 pp
AKAN: +267.83% · CISS: +135.23%
3M Horizon AKAN +67.04 pp
AKAN: +14.17% · CISS: -52.87%
6M Horizon CISS +36.52 pp
AKAN: -84.4% · CISS: -47.88%
1Y Horizon AKAN +383.74 pp
AKAN: +358.29% · CISS: -25.45%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKAN vs CISS. Trailing 12-month operating profitability (AKAN -1254.5% vs CISS 24.6%) and valuation multiples (AKAN N/M vs CISS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AKAN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$662,469
Gross Margin-12.0%
Op. Margin-1254.5%
ROE / Fwd P/E-60.9% · N/M
CISS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$36.2B
Gross Margin68.1%
Op. Margin24.6%
ROE / Fwd P/E17.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKAN BREAKDOWN
140d in phase · OBV ACCUMULATION
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact AKAN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CISS BREAKDOWN
64d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CISS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKAN Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $12.2M market capitalization and -1254.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CISS Moat Profile Scale & Operating Efficiency Moat
Marine Shipping Operator
Competes within the Marine Shipping value chain with $991,199 market capitalization and 24.6% operating margin.
OpEx & R&D Reinvestment 43.5% of Rev ($15.8B)
90D Engineering Disclosures 0 Published

Investor FAQ AKAN vs CISS Key Questions & Quantitative Answers

As of Nov 20, 2026, Akanda Corp. Common Shares (AKAN) captures the overall head-to-head institutional edge over C3is Inc. (CISS) on higher Unified Composite conviction (39.8/100 SELL vs. 33.6/100 SELL) after splitting the core matrix 3–5 (led by Valuation Multiples, Options & Positioning), while CISS wins 4–2 across the 6-pillar growth and valuation breakdown. AKAN trades at $4.23 (N/M Forward P/E, -1254.5% operating margin) versus CISS at $1.23 (N/M Forward P/E, 24.6% operating margin). Growth vs. Quality Trade-Off: AKAN earns the overall head-to-head edge with a stronger Unified Composite Score (39.8/100 SELL vs. CISS 33.6/100 SELL) and 4.82β · 524% Vol risk profile, whereas CISS leads top-line expansion (+249.0% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although AKAN compares more favorably head-to-head, both AKAN (39.8/100 SELL) and CISS (33.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: AKAN is currently in a Breakdown options structure phase (RSI 75.2); meanwhile CISS is in a Breakdown options structure phase (RSI 53.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CISS leads the Growth & Scale pillar: AKAN posts +21.9% YoY revenue growth and +0.0% YoY earnings growth on $662,469 TTM revenue (-12.0% gross margin, -1254.5% operating margin), compared with CISS at +249.0% YoY revenue growth and +193.3% YoY earnings growth on $36.2B TTM revenue (68.1% gross margin, 24.6% operating margin). On trailing 12-month operating scale, AKAN generates $662,469 in USD-normalized revenue versus $36.2B for CISS. In operating R&D and SG&A reinvestment, AKAN deploys N/A (0 90-day corporate R&D disclosures) versus 43.5% of Rev ($15.8B) (0 disclosures) for CISS.

AKAN screens cheaper on headline valuation multiples. AKAN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.5x EV/Revenue (unreported EBITDA margin), whereas CISS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (36.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKAN (-60.9% ROE) versus CISS (17.1% ROE) capital efficiency.

In options market volatility and institutional positioning, AKAN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (4.82β · 524% Vol realized risk). By comparison, CISS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (11.91β · 1054% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.